Pharmamarketeer

Novartis phase III PREVENT study of Cosentyx to treat patients with axial spondyloarthritis meets 16-week primary endpoint

Novartis, a leader reimagining rheumatology and immuno?dermatology, announced positive new data from the PREVENT trial evaluating the efficacy and safety of Cosentyx (secukinumab) in patients with nr-axSpA

Medhc-fases-banner
Advertentie(s)